Comparison 11.
Interferon versus control ‐ adverse events ‐ low risk of bias trials
| Outcome or subgroup title | No. of studies | No. of participants | Statistical method | Effect size |
|---|---|---|---|---|
| 1 Any adverse events | 1 | Risk Ratio (M‐H, Fixed, 95% CI) | Totals not selected | |
| 2 Serious adverse events | 1 | Risk Ratio (M‐H, Fixed, 95% CI) | Totals not selected | |
| 3 Haematologic | 2 | 2302 | Risk Ratio (M‐H, Fixed, 95% CI) | 2.41 [1.71, 3.39] |
| 3.1 Neutropenia | 1 | 626 | Risk Ratio (M‐H, Fixed, 95% CI) | 2.42 [1.43, 4.10] |
| 3.2 Thrombocytopenia | 1 | 626 | Risk Ratio (M‐H, Fixed, 95% CI) | 2.63 [1.61, 4.30] |
| 3.3 "Haematologic" | 1 | 1050 | Risk Ratio (M‐H, Fixed, 95% CI) | 1.44 [0.46, 4.52] |
| 4 Psychiatric events | 2 | 1676 | Risk Ratio (M‐H, Fixed, 95% CI) | 1.44 [0.94, 2.19] |
| 5 Infections | 2 | 1676 | Risk Ratio (M‐H, Fixed, 95% CI) | 1.51 [1.05, 2.16] |
| 6 Gastrointestinal | 2 | 11733 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.99 [0.87, 1.14] |
| 6.1 Nausea | 1 | 626 | Risk Ratio (M‐H, Fixed, 95% CI) | 1.24 [0.84, 1.81] |
| 6.2 Diarrhea | 1 | 627 | Risk Ratio (M‐H, Fixed, 95% CI) | 1.49 [0.92, 2.38] |
| 6.3 Abdominal pain | 1 | 626 | Risk Ratio (M‐H, Fixed, 95% CI) | 1.59 [0.94, 2.69] |
| 6.4 Dyspepsia | 1 | 626 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.95 [0.65, 1.38] |
| 6.5 Esophageal varices | 1 | 626 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.62 [0.42, 0.92] |
| 6.6 Hepatomegaly | 1 | 626 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.89 [0.62, 1.29] |
| 6.7 Splenomegaly | 1 | 626 | Risk Ratio (M‐H, Fixed, 95% CI) | 1.13 [0.81, 1.57] |
| 6.8 Non‐variceal bleeding | 1 | 1050 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.46 [0.14, 1.48] |
| 6.9 Hernia or obstruction | 1 | 1050 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.57 [0.19, 1.70] |
| 6.10 Gallbladder | 1 | 1050 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.89 [0.43, 1.86] |
| 6.11 Other pancreatico‐biliary | 1 | 1050 | Risk Ratio (M‐H, Fixed, 95% CI) | 1.44 [0.46, 4.52] |
| 6.12 Other gastrointestinal | 1 | 1050 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.76 [0.35, 1.63] |
| 6.13 Other liver | 1 | 1050 | Risk Ratio (M‐H, Fixed, 95% CI) | 1.03 [0.06, 16.44] |
| 6.14 Liver biopsy complications | 1 | 1050 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.75 [0.30, 1.85] |
| 7 Systemic symptoms | 1 | 6260 | Risk Ratio (M‐H, Fixed, 95% CI) | 1.82 [1.61, 2.05] |
| 7.1 Fatigue | 1 | 626 | Risk Ratio (M‐H, Fixed, 95% CI) | 1.34 [1.04, 1.72] |
| 7.2 Headache | 1 | 626 | Risk Ratio (M‐H, Fixed, 95% CI) | 2.22 [1.63, 3.02] |
| 7.3 Myalgia | 1 | 626 | Risk Ratio (M‐H, Fixed, 95% CI) | 4.05 [2.51, 6.53] |
| 7.4 Arthralgia | 1 | 626 | Risk Ratio (M‐H, Fixed, 95% CI) | 1.09 [0.81, 1.48] |
| 7.5 Pyrexia | 1 | 626 | Risk Ratio (M‐H, Fixed, 95% CI) | 3.92 [2.27, 6.76] |
| 7.6 Insomnia | 1 | 626 | Risk Ratio (M‐H, Fixed, 95% CI) | 1.13 [0.78, 1.63] |
| 7.7 Flu‐like illness | 1 | 626 | Risk Ratio (M‐H, Fixed, 95% CI) | 11.65 [4.24, 31.97] |
| 7.8 Asthenia | 1 | 626 | Risk Ratio (M‐H, Fixed, 95% CI) | 1.23 [0.82, 1.85] |
| 7.9 Irritability | 1 | 626 | Risk Ratio (M‐H, Fixed, 95% CI) | 2.44 [1.42, 4.21] |
| 7.10 Pruritus | 1 | 626 | Risk Ratio (M‐H, Fixed, 95% CI) | 1.58 [1.00, 2.49] |
| 8 Cardiopulmonary | 2 | 4402 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.96 [0.74, 1.25] |
| 8.1 Atherosclerosis | 1 | 1050 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.87 [0.45, 1.67] |
| 8.2 Arrhythmia | 1 | 1050 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.39 [0.10, 1.45] |
| 8.3 "Other cardiovascular" | 1 | 1050 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.82 [0.22, 3.05] |
| 8.4 Hypertension | 1 | 626 | Risk Ratio (M‐H, Fixed, 95% CI) | 1.12 [0.75, 1.67] |
| 8.5 Cough | 1 | 626 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.98 [0.63, 1.55] |
| 9 Musculoskeletal | 2 | 1676 | Risk Ratio (M‐H, Fixed, 95% CI) | 1.13 [0.82, 1.56] |
| 9.1 "Musculoskeletal" | 1 | 1050 | Risk Ratio (M‐H, Fixed, 95% CI) | 1.16 [0.68, 1.98] |
| 9.2 Back pain | 1 | 626 | Risk Ratio (M‐H, Fixed, 95% CI) | 1.11 [0.75, 1.66] |
| 10 Dermatologic | 2 | 2928 | Risk Ratio (M‐H, Fixed, 95% CI) | 2.78 [1.95, 3.97] |
| 10.1 Rash | 2 | 1676 | Risk Ratio (M‐H, Fixed, 95% CI) | 3.05 [1.61, 5.77] |
| 10.2 Injection erythema | 1 | 626 | Risk Ratio (M‐H, Fixed, 95% CI) | 73.94 [4.56, 1199.35] |
| 10.3 Alopecia | 1 | 626 | Risk Ratio (M‐H, Fixed, 95% CI) | 1.35 [0.84, 2.17] |
| 11 Metabolic | 1 | 3150 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.84 [0.35, 2.03] |
| 11.1 Electrolyte/water | 1 | 1050 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.88 [0.30, 2.61] |
| 11.2 Diabetes | 1 | 1050 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.52 [0.05, 5.67] |
| 11.3 Thyroid | 1 | 1050 | Risk Ratio (M‐H, Fixed, 95% CI) | 1.03 [0.15, 7.29] |
| 12 Neoplasms | 1 | 2100 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.74 [0.33, 1.65] |
| 12.1 Benign neoplasm | 1 | 1050 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.34 [0.04, 3.29] |
| 12.2 Cancer | 1 | 1050 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.84 [0.35, 2.02] |
| 13 Other system adverse events | 1 | 4200 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.82 [0.47, 1.41] |
| 13.1 Genitourinary | 1 | 1050 | Risk Ratio (M‐H, Fixed, 95% CI) | 1.42 [0.57, 3.50] |
| 13.2 Gynecologic | 1 | 1050 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.41 [0.08, 2.12] |
| 13.3 Neurologic | 1 | 1050 | Risk Ratio (M‐H, Fixed, 95% CI) | 1.03 [0.33, 3.18] |
| 13.4 Injury | 1 | 1050 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.41 [0.13, 1.31] |
| 14 Hospital admission | 0 | 0 | Odds Ratio (M‐H, Fixed, 95% CI) | 0.0 [0.0, 0.0] |